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Abstract
Objective: To investigate the relationships between self-reported and objectively
measured cognitive function prior to systemic therapy and subsequent well-being
outcomes over 24 months in older breast cancer survivors.
Methods: Data were from 397 women aged 60 to 98 diagnosed with non-metastatic
breast cancer in the Thinking and Living with Cancer Study recruited from
2010-2016. Cognitive function was measured at baseline (following surgery, prior to
systemic therapy) using neuropsychological assessments of attention, processing
speed, and executive function (APE), learning and memory (LM), and the self-reported
FACT-Cog scale. Well-being was measured using the FACT-G functional, physical,
social, and emotional well-being domain scales at baseline and 12 and 24 months
later, scaled from 0 (low) to 100 (high). Linear mixed-effects models assessed the
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relationships between each of baseline APE, LM, and FACT-Cog quartiles with
well-being scores over 24 months, adjusted for confounding variables.
Results: At baseline, older survivors in the lowest APE, LM, and FACT-Cog score
quartiles experienced poorer global well-being than those in the highest quartiles. At
24 months, older survivors tended to improve in well-being, and there were no differ-
ences according to baseline APE or LM scores. At 24 months, mean global well-being
was 80.3 (95% CI: 76.2-84.3) among those in the lowest vs 86.6 (95% CI: 83.1-90.1)
in the highest FACT-cog quartile, a clinically meaningful difference of 6.3 points (95%
CI: 1.5-11.1).
Conclusions: Among older breast cancer survivors, self-reported, but not objective
cognitive impairments, were associated with lower global well-being over the first
2 years of survivorship.
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1 | INTRODUCTION
Breast cancer survivors are the largest group of female cancer survi-
vors in the United States, and three-quarters of these women are
≥60 years old (“older”) at diagnosis.1-3 While survival rates are excel-
lent, older cancer survivors live with the effects of cancer treatments,
potential aging-related losses of physical and cognitive function,
multi-morbidity, and changes to financial, social, and living situa-
tions.4-8 In particular, cancer-related cognitive impairment has gained
attention as a central concern of older survivors.9-11 Cognitive prob-
lems at the time of diagnosis are important: although they may not be
clinically obvious, they may affect women's abilities to manage their
health after treatment, and may have substantial effects on daily func-
tion and well-being.11-15
However, the longitudinal well-being outcomes associated with self-
reported cognitive changes or neuropsychological deficits at the time of
diagnosis among older women with breast cancer have not yet been
established. Prior reports have been based on younger women, used
cross-sectional data, and/or did not include cognitive measures prior to
systemic therapy.11,15-19 Few studies have compared the associations
between objective and self-reported cognitive function with longitudinal
well-being in older breast cancer survivors. Self-reports may reflect sub-
tle changes in cognitive function that are not detected by formal neuro-
psychological assessments. Similar to self-reports of general health, they
may also reflect many factors, including psychological health, in addition
to true underlying cognitive function.20-24 Self-reported and objective
cognitive assessments have been reported to have poor correlations
within cancer survivor and general population samples,24 but their com-
parative associations with outcomes that are important to older cancer
survivors have rarely been investigated.
To fill these evidence gaps, we used data from a national,
prospective study of non-metastatic breast cancer survivors aged
≥60 years at the time of diagnosis: The Thinking and Living with
Cancer (TLC) Study. We investigated the relationships between objec-
tive and self-reported cognitive function prior to systemic therapy
(baseline) and changes in global, functional, physical, social, and emo-
tional domains of well-being at 12 and 24 months later. We hypothe-
sized that older breast cancer survivors with lower cognitive function
prior to systemic therapy would have persistently lower well-being over
time than those with higher cognitive function, and that these associa-
tions would be strongest for self-reports of cognitive function.24 These
results are intended to help identify older breast cancer survivors who
may be at risk for poorer well-being over time and to inform the devel-
opment and targeting of strategies to improve care and well-being for
this growing older breast cancer survivor population.
2 | METHODS
2.1 | Study design
This study was conducted at Georgetown University and affiliated
practices in the Washington, DC area, Memorial Sloan Kettering
Cancer Center in New York, Moffitt Cancer Center in Tampa, City of
Hope Comprehensive Cancer Center in Los Angeles, Hackensack
University Medical Center in New Jersey, Indiana University
(IU) School of Medicine in Indianapolis, and the University of Califor-
nia at Los Angeles (UCLA). IU and UCLA joined the study for labora-
tory support and IU for participant recruitment in 2016; data in this
report are from the five other sites. All Institutional Review Boards
approved the protocol (NCT03451383). Details about the study are
provided elsewhere.25 The present analysis uses data from all partici-
pants enrolled from 2010 through 2016 who completed follow-up at
12- and 24-months post-baseline.
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2.2 | Study participants
Eligible study participants were English-speaking women aged
60 years and over with a new, primary non-metastatic breast cancer
(AJCC v.6 stage 0-3). Exclusion criteria were having a history of
stroke, head injury, a major Axis I psychiatric disorder, or neurode-
generative disorder. Women were ineligible if they had a history of
other cancers with active treatment in the past 5 years or any sys-
temic therapy. Women were screened for ability to complete the
study based on hearing, vision, and baseline MMSE scores of 24+
and WRAT-4 reading level of third grade or higher. The consent rate
among eligible women was 39.2% (range across sites: 17.2%-83.9%;
median 67.6%). Among those who remained alive and eligible for
inclusion, follow-up rates were 75.2% and 74.9% at 12 months and
24 months, respectively. TLC also recruited frequency-matched con-
trols (based on 5-year age groups, education level, race, and site)
using the same eligibility criteria and assessments. Consent rate
among eligible controls was 96.2% (range across sites: 92.8% to
100%; median 95.0%), with 89.2% retention at 12 months and
81.8% at 24 months (Figure 1).
2.3 | Measures
2.3.1 | Well-being outcomes
The well-being outcomes were measured using the FACT-G func-
tional, physical, social, and emotional domain scales at baseline and
12 and 24 months later, scaled from 0 to 100 with higher scores rep-
resenting better well-being.26-28 The domains were considered sepa-
rately, and combined to create a global score. As per Webster et al,26
minimum clinically important differences in scores on the 0 to
100 scale were considered to be: ≥3.6 points (global well-being); ≥8.3
points (functional well-being), ≥8.3 points (physical well-being), and
≥12.5 points (emotional well-being). General population and cancer
survivor norms on these scales for US adults are available from
Brucker et al.27
2.3.2 | Neuropsychological assessments
A neuropsychological assessment was administered during the base-
line (pre-systemic therapy) study interview to assess domain-specific
cognitive functions. The assessment included six tests of attention,
processing speed, and executive functioning (collectively, APE) and
five tests of learning and memory (collectively, LM). We used tests of
cognitive domains that are sensitive to aging-related changes and that
have established validity and reliability in older populations.25 Using
principal components analysis, we previously confirmed the domain
structure of the APE and LM measures and their reliability over time
within this sample.25 We z-standardized the composite APE and LM
scores using the baseline age- and education-group matched healthy
control means and standard deviations (SDs), to give a mean of 0 and
SD of 1. We categorized the scores into quartiles, in order to compare
changes in well-being over time among older women across the base-
line distribution of cognitive function.
2.3.3 | Self-reported cognitive function
Self-reported cognitive function was assessed using the FACT-Cog
scale at baseline.28 The FACT-Cog has excellent test-retest reliability
and has been validated among breast cancer survivors as reflecting
cognitive functions assessed by neuropsychological measures and
quantitative electroencephalography, independently of depressive
symptoms.29 The FACT-Cog items assess perceived cognitive func-
tioning over the past 7 days according to four sub-scales: (a) Perceived
Cognitive Impairments; (b) Perceived Cognitive Abilities; (c) Impact on
Quality of Life; and (d) Comments from Others. The total scale has a
Chronbach's alpha of 0.96. A previous validation study indicates a
minimum clinically important difference of 6.9 points on the FACT-
Cog scale among breast cancer survivors.30
The range of the FACT-Cog scale was 0 (low) to 148 (high); we
categorized scores into quartiles to allow comparability with estimates
for well-being outcomes for individuals at equivalent locations on the
distributions of each of FACT-Cog, APE, and LM scores. The quartile
F IGURE 1 Study flow diagram, older breast cancer survivors, Thinking and Living with Cancer Study (recruitment to end of 2016
calendar year)
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cutoff values were <121 points (lowest), 121 to 134 points, 134 to
141 points, and >141 points (highest). Examination of the domain-
specific scores within each quartile of the total FACT-Cog scale score
indicated that the Perceived Cognitive Impairments and Perceived
Cognitive Abilities domains were the primary drivers of variability in
total scale score. The Impact on Quality of Life and Comments from
Others domains demonstrated ceiling effects, with little differences in
these domain-specific scores between individuals in the lowest vs
highest total FACT-Cog score quartiles (Table S1).
2.3.4 | Covariates
Potential confounding variables were age (continuous), race/
ethnicity (white non-Hispanic, and non-white), marital status
(married or living as married; not married), word reading score as a
marker of cognitive reserve (continuous score on the Wide Range
Achievement Test Word Reading sub-test, fourth edition, or
WRAT-4), receipt of radiation (yes; no), receipt of chemotherapy
(yes; no), number of comorbidities, number of limitations to instru-
mental activities of daily living (IADLs), and study recruitment site.
Because the study participants predominantly identified as white
non-Hispanic, we could not further stratify the “non-white” group
in statistical analyses.
2.4 | Statistical analysis
Baseline descriptive characteristics of the study sample at baseline
were calculated. We examined the unadjusted correlations between
baseline APE, LM, and FACT-Cog scores (continuous) and baseline
well-being domain scores (continuous). With separate models for each
of the three cognitive measures, we used linear mixed-effects models
to test the hypotheses that older breast cancer survivors with lower
baseline APE, LM, and FACT-Cog scores would have persistently
poorer global, functional, physical, social, and emotional domain
scores over the 24-month follow-up. The linear mixed-effects models
allowed us to account for the within-person correlations in the out-
comes due to the repeated measures over time by incorporating
subject-specific random effects. The models were adjusted for age,
race/ethnicity, marital status, word reading score, receipt of radiation
(yes vs no), receipt of chemotherapy (yes vs no), study recruitment
site, in addition to a variable for time (in years) and a statistical inter-
action between time and the baseline cognitive measure, to allow the
well-being outcome slopes (rate of change over time) to vary by base-
line level of cognitive function.
Since study drop-out or death after the baseline can be informa-
tive with respect to the outcome, we calculated inverse probability of
censoring weights (IPCWs) to account for any differential loss to
follow-up due to study attrition or mortality.31 The IPCW is the
inverse of the probability of study attrition through a given study time
point, for person i at time point t. We estimated these probabilities
using logistic regression models including baseline covariates as
predictors of study attrition: age, race/ethnicity, marital status, study
recruitment site, pre-diagnosis self-reported physical function, fatigue
symptom score, number of comorbidities, number of prescription
medications, FACT-Cog score, depressive symptom score, and timed
get-up-and-go. All models incorporated the IPCWs.
TABLE 1 Baseline characteristics, Thinking and Living with
Cancer Study, 2010 to 2016, N = 397
Baseline characteristic
Total N (%) or
Mean (SD)
Age (Mean; SD) 68.0 (6.0)
Years of education (Mean; SD) 15.2 (2.2)
Race/ethnicity
White (Non-Hispanic) 314 (79.1%)
Non-White 83 (20.9%)
Marital status
Married or living as married 229 (60.6%)
Not married 149 (39.4%)
WRAT-4 literacy score (Mean; SD) 111.5 (15.3)
Number of comorbidities (Mean; SD) 2.6 (1.9)
Number of IADL limitations (Mean; SD) 0.44 (1.02)
Fatigue scale score
Mean (SD) 43.15 (8.49)




Mean (SD) 29.2 (8.2)
Treatment modality
Chemo +/− HT 111 (29.0)
HT only 272 (71.0)
AJCC tumor stage
Stage 0 50 (12.7)
Stage 1 214 (54.3)
Stage 2 109 (27.7)
Stage 3 21 (5.3)
FACT-G Global well-being score (Mean;
SD)
81.15 (12.86)
FACT-G Functional well-being score
(Mean; SD)
74.43 (20.22)
FACT-G Physical well-being score (Mean;
SD)
83.37 (16.27)
FACT-G Social well-being baseline score
(Mean; SD)
85.96 (16.88)
FACT-G Emotional well-being baseline
score (Mean; SD)
82.04 (17.23)
Note: US general adult female population FACT-G norms, scaled from 0 to
100, are: 73.7 (global), 65.35 (functional), 78.93 (physical), 70.71 (social),
and 80.83 (emotional). US adult female cancer survivor FACT-G norms,
scaled from 0 to 100, are: 76.02 (global), 69.64 (functional), 77.14
(physical), 79.64 (social), and 77.92 (emotional). From Brucker et al,
2005.18
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For each model set, we extracted the predicted adjusted mean
values and their 95% confidence intervals for each well-being out-
come scale at each time point, and estimated the differential between
the highest and lowest baseline cognitive function quartiles for each
time point. We graphically presented change over time for each of the
well-being outcomes according to baseline cognitive function quar-
tiles and added the corresponding fully adjusted slope for the healthy
cancer-free controls, to visually benchmark the degree of change over
time in well-being outcomes that may be attributable to breast cancer,
over and above aging over time alone. All statistical analyses were
completed using SAS 9.0 (SAS Institute, Cary, NC).
2.4.1 | Sensitivity analyses
We conducted sensitivity analyses with mixed-effects models that
were adjusted for our original model covariates, plus two iterative
adjustments for baseline physical health and mental health indicators:
first, we included number of comorbidities and limitations to instru-
mental activities of daily living (IADLs), and second, we included
depressive symptom score (Center for Epidemiologic Studies
Depression Scale) and anxiety symptom score (State-Trait Anxiety
Inventory Scale). Because the causal directions of associations
between these factors and cognitive function remain uncertain and
could be bidirectional,20,21 we consider these analyses exploratory
and hypothesis-generating for future studies.
3 | RESULTS
The mean age of the breast cancer survivors was 68 years (SD:
6 years; range: 60-98 years). Mean years of education was 15.2 years
(SD: 2.2 years), and 79.1% reported that they were white and non-
Hispanic (Table 1). Table 2 shows the unadjusted correlation
TABLE 2 Unadjusted correlation coefficients between baseline APE, LM, and FACT-Cog scores with global and domain-specific well-being
scores, Thinking and Living with Cancer Study, 2010 to 2016, N = 397
Baseline cognitive score
Baseline well-being score
Global well-being Functional well-being Physical well-being Social well-being Emotional well-being
APE 0.11 0.13 0.14 0.02 −0.01
P-value (.03) (.02) (.01) (.70) (.92)
LM 0.08 0.12 0.10 −0.01 0.06
P-value (.11) (.12) (.05) (.82) (.27)
FACT-Cog 0.43 0.39 0.39 0.15 0.27
P-value (<.0001) (<.0001) (<.0001) (.004) (<.0001)
Note: The well-being outcomes are scaled from 0 (low) to 100 (high).
Abbreviations: APE, attention processing speed, and executive function; LM, learning and memory.
F IGURE 2 Adjusted global well-being scores over 24 months of follow-up, according to baseline attention, processing speed, and executive
function quartile (Panel A), baseline learning and memory quartile (Panel B), and baseline FACT-Cog quartile (Panel C), all with cancer-free
controls included for comparison
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coefficients between baseline APE, LM, and FACT-Cog scores with
baseline well-being domain scores.
3.1 | Cognition and global well-being
Figure 2 shows the longitudinal trends in fully adjusted global well-
being scores, according to baseline APE (Panel A), LM (Panel B), and
FACT-Cog quartiles (Panel C). The model generating the estimates for
this figure included the cancer-free controls to provide a visual bench-
mark for comparison with the trends in survivors. As shown in
Figure 2, at baseline, the adjusted mean global well-being scores going
from the highest to lowest APE quartile were: 85.9 (SE: 1.29), 85.9
(SE: 1.78), 84.3 (SE: 1.84), and 80.1 (SE: 1.83). For LM quartiles, the
adjusted mean global well-being values were: 85.1 (SE: 1.29), 82.2
(SE: 1.68), 83.7 (SE: 1.82), and 78.5 (SE: 1.98). For FACT-Cog quartiles,
the adjusted mean global well-being values were 87.99 (SE: 1.20),
86.03 (SE: 1.88), 82.26 (SE: 1.64), and 74.90 (SE: 1.78) (Figure 1). The
differences in adjusted baseline global well-being between survivors
in the lowest vs highest APE, LM, and FACT-Cog quartiles were 5.8,
6.6, and 13.1 points out of 100, respectively, which were all clinically
meaningful differences. At the 24-month follow-up, there were no
statistically or clinically meaningful differences in global well-being
according to baseline APE or LM scores (Table 3; Table S2). The mean
predicted 24-month global well-being score in the highest baseline
FACT-Cog quartile was 86.6 (95% CI: 83.1-90.1), and in the lowest
FACT-Cog quartile was 80.3 (95% CI: 76.2-84.3), a clinically meaning-
ful difference of 6.3 points (95% CI: 1.5, 11.1; Table 3; Table S2).
3.2 | Cognition and domain-specific well-being
Changes over time in the functional and physical well-being domains
were similar to those observed for global well-being for all three cog-
nitive measures (Figures S1 and S2). The fully adjusted baseline differ-
ences between the highest vs lowest FACT-Cog quartiles were
considered clinically meaningful for these two domains (16.8 for func-
tional well-being; 16.4 for physical well-being; Figures S1 and S2).
Social well-being declined over time and emotional well-being
improved over time, on average, among the breast cancer survivors
(Figures S3 and S4). At the 24-month follow-up, there were negligible
differences in predicted well-being domain scores according to base-
line APE and LM (Table 3). The predicted differences between the
highest vs lowest baseline FACT-Cog score quartiles at the 24-month
follow-up were statistically significant but not clinically meaningful for
physical, social, and emotional well-being (Table 3).
3.3 | Sensitivity analyses
When physical health indicators and mental health indicators were
added to models, the physical health indicators generally changed
the effect estimates very little, and the mental health indicators
attenuated the effect estimates towards the null for the FACT-Cog
(Table S3).
4 | DISCUSSION
This is the first large, prospective study of self-reported and objective
cognitive function prior to systemic therapy and their relationships
with changes in multi-domain well-being among older women over
the first 2 years of breast cancer survivorship. Prior to systemic ther-
apy, older breast cancer survivors with poorer objective and self-
reported cognitive function had clinically meaningfully poorer global
well-being scores, after accounting for key confounders. The women
in this study tended to improve in well-being over time and the
observed differences in well-being narrowed. However, there were
persistent clinically meaningful differences in global well-being over
time for women who reported the most cognitive impairments and
lowest perceived cognitive abilities prior to their systemic therapy.
Well-being was more closely related to self-reported cognitive
TABLE 3 Differences in mean 24-month well-being scores according to baseline cognitive measures, Thinking and Living with Cancer Study,
2010 to 2016, N = 397
Baseline cognitive measure
Adjusted mean 24-month well-being score (95% CI)
Global well-being Functional well-being Physical well-being Social well-being Emotional well-being
APE (Q4-Q1 difference) −0.01 (−5.59, 5.58) −5.89 (−14.48, 2.69) −0.72 (−6.6, 5.15) 8.67 (−0.61, 17.95) −0.93 (−6.75, 4.89)
P-value .997 .178 .809 .067 .754
LM (Q4-Q1 difference) 0.41 (−5.09, 5.91) −1.32 (−9.85, 7.21) 1.51 (−4.25, 7.27) 0.96 (−8.28, 10.2) 0.56 (−5.02, 6.15)
P-value .884 .761 .607 .838 .843
FACT-Cog (Q4-Q1 difference) 6.31 (1.49, 11.14) 5.97 (−1.61, 13.56) 5.41 (0.3, 10.53) 8.64 (0.4, 16.89) 5.95 (1.06, 10.84)
P-value .011 .122 .038 .040 .017
Note: All estimates are adjusted for baseline age, race/ethnicity, marital status, WRAT-4 literacy score, study recruitment site, receipt of radiation, receipt
of chemotherapy, time (in years) and the interaction between time (in years) and the baseline cognitive measure. Inverse probability of censoring weights
(IPCWs) were applied to all models to account for differential loss-to study follow-up. The well-being outcomes are scaled from 0 (low) to 100 (high).
Abbreviations: APE, attention, processing speed, and executive function; LM, learning and memory; Q4, quartile 4 (highest); Q1, quartile 1 (lowest).
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function than to the neuropsychological test measures, consistent
with prior research indicating that self-reported and objective cogni-
tive function do not consistently correlate.24 We add new evidence
indicating that, among older breast cancer survivors, self-reported
cognitive function prior to systemic therapy is associated with a clini-
cally meaningful decrement in global well-being over the first
24 months of survivorship.
4.1 | Comparison to other literature
Our results are consistent with a cross-sectional study that correlated
self-reports of cognitive function with well-being measures in older
breast cancer survivors.32 We identified three studies that investigated
cross-sectional and longitudinal associations between neuropsychological
test scores and well-being among breast cancer survivors;17,18,33 how-
ever, their findings are inconsistent. Previous research has indicated that
self-reported cognitive function is not only associated with depressive
symptoms but also has relationships with well-being outcomes indepen-
dently of depressive symptoms.29 In our sensitivity analysis, we observed
that mental health indicators attenuated the relationship between
self-reported cognitive function and well-being, but since these measure-
ments were all taken at the same time, we cannot discern whether
mental health is a confounder or mediator of this relationship. The role
of mental health in the relationships between self-reported cognitive
function and survivorship outcomes among older breast cancer survivors
warrants further investigation.
4.2 | Study limitations
A limitation of this study is that it was conducted among mostly white,
highly educated women who presented to mainly academic medical
centers in urban areas. We observed higher mean global well-being
scores in our sample relative to the established norms for the FACT
scales (mean: 81.2; SD: 12.9 in our sample, vs mean: 73.7; SD: 17.2 in
the US general adult female population and mean: 76.02; SD: 15.09 in
the US adult female cancer survivor population), which was mostly
driven by higher than average scores in the functional and social
domains.27 The higher mean well-being scores that we observed may
reflect the sociodemographic composition of our study, and we
caution the generalization of our findings outside of this population
subgroup. A high priority for future research on cancer and aging is to
include diverse older population samples to improve the generalizabil-
ity of findings, and to characterize and understand any potential
health disparities in well-being and other outcomes that are relevant
to older cancer survivors.
4.3 | Clinical implications
In this study population, older women with relatively low objective
and self-reported cognitive function prior to systemic therapy tended
to recover somewhat in well-being over time, which should be a
reassuring finding. However, older women who reported the lowest
pre-systemic therapy cognition had clinically meaningful decrements
in global well-being over the first 2 years of breast cancer survivor-
ship. In this study, perceived cognitive impairments and perceived
cognitive abilities were the sub-domains of self-reported cognitive
function that appeared to primarily drive the observed associations.
A next step is to determine whether older women who present with
cognitive complaints at the time of their diagnosis might need detec-
tion and intervention to improve well-being over the course of cancer
survivorship care. Our findings are consistent with literature
supporting the use of geriatric assessments in oncology practice,
which include brief self-reports of cognitive function.34-36
4.4 | Conclusions
Prior to systemic therapy, older breast cancer survivors with poorer
objective and self-reported cognitive function had clinically meaning-
fully poorer global well-being scores, after accounting for key
confounders. These women tended to improve in their well-being
over time throughout the first 2 years of cancer survivorship. How-
ever, there were persistent clinically meaningful differences in global
well-being over time for women who reported the most cognitive
problems prior to systemic therapy. Well-being domains were more
strongly associated with self-reported than objective cognitive
function measures, supporting the clinical utility of self-reports of
cognitive function for understanding well-being over the early phase
of survivorship for older breast cancer survivors. The present study is
a novel early contribution in this area, at a time when older cancer
survivors make up an increasing share of the general population in the
United States and elsewhere.
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